PharmaSGP Holding SE / DE000A2P4LJ5

Publication of inside information in accordance with Article 17 of Regulation (EU) No. 596/2014 Gräfelfing, July 11, 2025 – The Management Board of PharmaSGP Holding SE (ISIN: DE000A2P4LJ5) has today decided, based on an evaluation of current data on business development completed today, to adjust the forecast for consolidated revenues of the PharmaSGP Group for the full year 2025. In view of the business development to date, the Management Board now expects consolidated revenues for the 2025 fiscal year to be in the range of €132.0 million to €138.0 million. The company had previously forecasted consolidated revenues for the 2025 fiscal year in the range of €122.0 million to €128.0 million. Adjusted EBITDA is still expected to be between €37.0 million and €39.0 million, which, taking into account the adjusted revenues forecast, corresponds to an adjusted EBITDA margin of 26.8% to 29.5%. The previous forecast implied an adjusted EBITDA margin of 28.9% to 32.0%. The adjusted forecast for fiscal year 2025 continues to take into account, among other things, the ongoing high level of uncertainty in the geopolitical and global economic situation. Further developments over the course of the year and potential consequences for Germany and Europe cannot be conclusively assessed at this time. The preliminary figures for the first half of 2025 will be published as planned on September 11, 2025. The half-year financial report will be published on September 25, 2025. Note: Adjusted EBITDA is not a measure in accordance with IFRS. Information on the adjustments used to derive adjusted EBITDA is available in the 2024 Annual Report of PharmaSGP Holding SE on page 70 (available at https://ir.pharmasgp.com).   CONTACT cometis AG
Jakob Hafer
Phone: +49-611-20585522
Email: ir@pharmasgp.com   ABOUT PHARMASGP HOLDING SE PharmaSGP is a leading consumer health company with a diversified portfolio of over-the-counter (OTC) pharmaceuticals and other healthcare products that are marketed with a focus on the pharmacy distribution channel. These products are mostly based on natural active pharmaceutical ingredients with documented efficacy and few known side effects. The Company’s core brands cover chronic indications, including rheumatic pain, nerve pain and other age-related ailments. In Germany, PharmaSGP is the market leader for systemic chemical-free pain remedies with its brand families RubaXX® for rheumatic pain and Restaxil® for neuralgic pain. Furthermore, PharmaSGP also offers leading products against sexual weakness and vertigo symptoms. Since introducing the first product from the current product portfolio in 2012, PharmaSGP has successfully established its business model in other European countries, including Austria, Italy, Belgium, Spain and France. In September 2021, the product portfolio was expanded by the brands Baldriparan®, Formigran®, Spalt® and Kamol®, thus also strengthening or developing the indications pain and sleep disorder. The sales territory was expanded to include Switzerland and Eastern Europe. In 2024, PharmaSGP generated revenues of €118.8 million at an adjusted EBITDA margin of 31.3%. In order to further expand its competitive position, PharmaSGP plans to increase the number of indications covered by PharmaSGP’s product offering, increase PharmaSGP’s European footprint, and accelerate its growth strategy especially by capitalizing on selected M&A opportunities.